Answers are grounded in this paper and cite their sources.
Although human immunodeficiency virus-infected people aged > or =50 years have a blunted CD4 cell recovery when receiving highly active antiretroviral therapy (HAART), there are few data on mortality. Mortality rates were studied for 253 individuals aged > or =50 years and a younger group of 535 people in a retrospective cohort; for untreated persons in each age group, the proportions surviving at 3 years were 83% and 70% (P<.01), respectively. No significant difference in the survival rate was found between the older (83%) and younger (89%) patients who received HAART (P=.29). The hazard ratio for death in the older untreated group was 2.4 (95% confidence interval [CI], 1.4-3.9) when exposed to HAART. However, compared with older untreated patients, the hazard ratio for death decreased to 0.28 (95% CI, 0.15-0.52) for treated older adults. The effect of HAART substantially improves the survival rate for older individuals and supports the importance of treatment in this group.
No takes yet. Share an insight, caveat, or question.
Perez et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: